Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLAMING dual biologic therapy for induction-resistant refractory Crohn's disease
2023-506626-37-00Phase 2Authorised
- Sponsor
- Military Institute of Medicine – National Research Institute
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Crohn's disease comparing Vedolizumab + ustekinumab with Vedolizumab + infliximab (2 arms). Primary endpoint: Sustained corticosteroid-free remission at Week 52. Planned start May 2024; status: authorised.
02
Drugs
ustekinumabinfliximabvedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2023-506626-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506626-37-00.